Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genenta Science SpA Sponsored ADR ( (GNTA) ) has shared an update.
On April 29, 2025, Genenta Science S.p.A. held its Annual Ordinary Shareholders’ Meeting in a virtual format, where shareholders approved the statutory financial statements for the year ending December 31, 2024, and appointed three directors to the Board, including Dr. Francesco Galimi as a new member. Dr. Galimi brings over 30 years of experience in healthcare R&D, having held leadership roles in biotech and large pharma companies. The newly appointed directors met on April 30, 2025, to confirm Mr. Pierluigi Paracchi as CEO, with compensation details for the directors also finalized.
The most recent analyst rating on (GNTA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. is a biotechnology company based in Milan, Italy, focusing on the development of innovative gene therapies. The company is engaged in research and development within the healthcare sector, particularly targeting cancer treatment through gene transfer technologies.
Average Trading Volume: 352,854
Technical Sentiment Signal: Buy
Current Market Cap: $118.7M
For a thorough assessment of GNTA stock, go to TipRanks’ Stock Analysis page.